Business Overview

Prime Medicine is a clinical-stage gene editing company built on prime editing — a technology invented in David Liu's lab at the Broad Institute in 2019 and licensed exclusively to PRME. Prime editing is distinct from CRISPR/Cas9 (which cuts both DNA strands) and base editing (which converts single bases): it can make any type of edit — corrections, insertions, deletions — without creating double-strand breaks. This matters because double-strand breaks cause unintended insertions/deletions and translocations. PRME's clinical data in CGD showed zero detectable off-target edits, zero translocations, zero bystander edits (8-K, Jan 12, 2026: "No detectable off-target editing, large deletions, or translocations in any lead program," confirmed across 550 potential off-target sites in edited CD34+ cells and in vivo mouse bone marrow at 16 weeks). No other gene editing company has published comparable safety data in clinical-stage programs.

The company has two delivery platforms. Ex vivo: electroporation of hematopoietic stem cells (used for CGD, potentially for CAR-T). In vivo: a proprietary liver-targeted lipid nanoparticle (LNP) that achieved >70% hepatocyte editing in humanized mice and >50% in non-human primates at clinically relevant doses. The LNP is modular — 6 of 8 components are identical across liver programs, enabling manufacturing and regulatory synergies.

PRME's PASSIGE technology (Prime Assisted Site-Specific Integrase Gene Editing) enables large gene-sized insertions, addressing diseases like cystic fibrosis where the mutation spectrum is too broad for point correction. No other gene editing platform has demonstrated this capability in preclinical models.

Revenue model. PRME generates near-zero product revenue. Current revenue (≈$5M/year) comes from the BMS collaboration agreement ($55M upfront + $55M equity investment in Sep 2024), recognized on a cost-input basis from $66.7M of deferred revenue. Future economics are milestone-driven: up to $3.5B from BMS on CAR-T development and commercialization, plus royalties. CFF has committed $39M in non-dilutive funding for cystic fibrosis, though $18M of this is recorded as a liability (repayable on change of control at up to 2.5x).

The intellectual property position is foundational. PRME holds an exclusive license from the Broad Institute covering prime editing in the prevention or treatment of human disease. Six U.S. and 12 ex-U.S. patents have issued. These are not narrow method claims — they cover any permutation of prime editing technology. The Broad license was amended twice in September 2025 (4th and 5th Amendments plus Side Letter No. 2) to adjust development milestones following the May 2025 strategic restructuring.

Pipeline.

Sources: PRME 10-K (Feb 28, 2025), 10-Q (Nov 7, 2025), 8-K corporate presentations (Sep 8, 2025 and Jan 12, 2026).

Financial Profile

Four-Year Arc

PRME went public in October 2022. The financial trajectory tells a clear story: rapid scaling of R&D spend through 2024, followed by an abrupt strategic restructuring in May 2025.

Operating expenses plateaued at ≈$205M in FY2023-2024, then the May 2025 restructuring cut approximately 25% of the workforce (8-K, May 19, 2025) and deprioritized the CGD program. However, Q3 2025 quarterly opex ($55.2M, annualized $221M) was virtually unchanged from Q3 2024 ($54.4M). The explanation: personnel costs dropped 27% (-$4.0M) but facility costs surged 47% (+$3.6M) from the new 60 First Street Cambridge headquarters lease initiated in 2024. The lease is a fixed obligation that does not flex with headcount.

Cash position and runway. As of September 30, 2025: $213M in cash, cash equivalents, and investments. Management guided this is "sufficient to fund operating expenses and capital expenditure requirements into 2027." Quarterly burn rate has been $50-55M. At $52M/quarter, $213M funds approximately 4 quarters from Sep 30 — i.e., through Q3 2026 — not "into 2027." The gap likely assumes further opex reduction in FY2026 and/or additional BMS milestone payments.

Capital structure. No debt. Shares outstanding have grown from ≈72M at IPO to ≈180.5M (as of Oct 31, 2025) — 2.5x dilution. Stock-based compensation runs ≈$26M/year (13% of opex), elevated for a company at this market cap. The $300M ATM facility with Jefferies has not been tapped as of the last filing.

Key balance sheet items not captured in standard metrics:

• BMS deferred revenue: $66.7M ($7.0M current + $59.8M long-term) — represents future R&D obligations, not free cash
• CFF research funding liability: $18.0M — recorded as a liability, repayable at up to 2.5x on change of control
• PRME's investment in BEAM equity: $4.9M (fair value of BEAM shares held by PRME). Separately, BEAM holds 1,608,337 shares of PRME common stock (received under the 2019 collaboration agreement), valued at ≈$7.1M at current prices. These are two distinct cross-holdings, not duplicative.
• Operating lease obligations: ≈$118M (long-term), reflecting the Cambridge HQ

Sources: PRME 10-K (Feb 28, 2025) lines 8854-8986; 10-Q (Nov 7, 2025) lines 282-498, 718-738; S-3 shelf registration (Dec 13, 2024).

Competitive Position

Wilson Disease (PM577) — Defensible

Wilson disease affects >20,000 patients in the US and Europe. It is caused by loss-of-function mutations in ATP7B, disrupting copper homeostasis and leading to liver failure, neurocognitive decline, and premature death. Current standard of care is chronic chelation therapy (penicillamine, trientine) — no approved curative treatment exists.

PRME's PM577 targets the H1069Q mutation (30-50% of Western patients) and R778L (predominant in Asia). Preclinical data presented at AASLD (Nov 2025) showed: correction of both mutations in fully humanized mouse models, ≈75% reduction in liver copper, ≈80% decrease in urinary copper, and ≈100% increase in fecal copper excretion — all at clinically relevant LNP doses. Correction of 20-30% of hepatocytes is predicted to be curative based on the biology.

The competitive landscape for gene editing in Wilson Disease is thin:

UX701 uses adeno-associated virus (AAV) gene therapy — a fundamentally different approach (gene addition vs. gene correction). AAV-based therapies face durability concerns, immunogenicity, and liver toxicity at therapeutic doses. Prime editing corrects the endogenous gene, leaving it under native regulatory control. No other gene editing company has disclosed a Wilson Disease program.

Assessment: HIGH defensibility. First-mover in gene editing, minimal competition, large unmet need, strong preclinical data.

AATD (PM647) — Contested

Alpha-1 antitrypsin deficiency affects ≈200,000 patients in the US and EU (20-30K diagnosed). The PiZ mutation (E342K) causes both loss of functional AAT protein (lung disease) and toxic protein aggregation (liver disease). Current therapy is chronic AAT augmentation (≈$100K/year, $4B+ market), which addresses only the lung component.

PM647 demonstrated restoration of healthy M-AAT protein into the normal human range in fully humanized mouse models at clinically relevant doses. PRME's unique claim: prime editing can correct the mutation back to wild-type without bystander edits, potentially addressing both lung and liver manifestations.

The competitive landscape is crowded:

BEAM-302 is dramatically ahead — 25+ patients dosed, FDA Regenerative Medicine Advanced Therapy (RMAT) designation, pursuing accelerated approval. PRME is at least 2-3 years behind the leader.

Critical risk: BEAM has filed arbitration (April 2025) alleging PM647 infringes on BEAM's exclusive license to prime editing for transition mutations. The PiZ mutation (E342K) is a G-to-A transition, which plausibly falls within BEAM's contractual field. If the arbitration panel rules against PRME, it could be ordered to cease work on AATD and transfer the program to BEAM. This is discussed in detail in the Key Risks section.

Assessment: LOW defensibility. 6th entrant, years behind leader, under active legal challenge.

Cystic Fibrosis — Long Option

CF affects 80,000+ patients in the US and EU. Trikafta (Vertex) generates $10B+ annually but serves only ≈90% of genotypes and does not address the underlying genetic defect. PRME's approach uses PASSIGE to insert a functional CFTR superexon, potentially addressing >93% of all CF patients with a single curative therapy delivered to the lung.

This is early-stage (preclinical, proof-of-concept data expected 2026). CFF has committed $39M. Lung delivery of LNP/AAV for gene editing is an unsolved problem across the industry. High technical risk, but massive TAM and non-dilutive funding mitigate downside.

Platform Moat

The Broad Institute license gives PRME exclusive rights to prime editing for human therapeutics. David Liu's foundational patents cover the core technology. Broad's "inclusive innovation" model allows march-in rights for gene targets PRME isn't actively pursuing, but Broad has not exercised this right to date.

The September 2025 license amendments likely adjusted development milestones post-restructuring. Broad retains termination rights if PRME fails commercially reasonable efforts. The license creates a genuine moat — any competitor wanting to use prime editing must either develop a non-infringing approach or license from Broad (which is restricted by PRME's exclusive rights in the therapeutic field).

Sources: PRME 10-K (Feb 28, 2025) lines 943-1100, 1291-1494; 10-Q (Nov 7, 2025) lines 1392-1437; 8-K presentations (Sep 8 and Jan 12, 2026); BEAM 10-Q (Nov 4, 2025) lines 1782-1803; cross-corpus transcript searches for Wilson Disease and AATD competitors.

Management and Governance

Leadership Transition

On May 18, 2025, CEO Keith Gottesdiener resigned simultaneously with the strategic restructuring announcement. Allan Reine, M.D. (previously CFO) was appointed CEO. Jeff Marrazzo was named Executive Chair.

The transition signal: this is now a capital allocation and survival story. Reine — the finance executive, not the scientist — was chosen to manage burn rate and runway. Marrazzo, co-founder of Spark Therapeutics (sold to Roche for $4.8B in 2019), brings gene therapy commercialization and M&A experience. In November 2025, Matthew Hawryluk, Ph.D., M.B.A. was hired as Chief Business Officer to lead partnership development.

Reine's compensation: $665K base + 60% target bonus. Change-of-control severance: 18 months base + bonus + accelerated vesting.

Insider Ownership — Open Market Purchases (Form 4 Code P)

This is unusual both in magnitude and breadth. ARCH ($10M into a $350M market cap company), David Liu (the inventor buying his own science four times at the trough), and the newly appointed CEO all buying with personal cash within weeks of restructuring. No insider selling in this period.

Robert Nelsen (ARCH founder) sits on the board, providing governance oversight alongside his fund's investment.

Option Repricing

A special stockholder meeting (August 1, 2025) approved repricing of 8,285,387 outstanding options from exercise prices of $7.68-$17.00 down to $4.04 (closing price on repricing date). The repricing included retention clawback provisions: options revert to original price if employees leave before 12-month (employees) or 18-month (executives/directors) retention dates. Vote: 71.6M for, 13.5M against. This was a pragmatic retention measure following the 25% workforce reduction — all options were deeply underwater and had zero retention value.

Capital Allocation Track Record

Stewardship: C+, improving. The company burned through ≈$690M of accumulated deficit over three years while pursuing a broad pipeline that proved unsustainable. The February 2025 10-K disclosed going concern doubt. The November 2025 10-Q resolved this: management stated $213.3M in cash and investments "will be sufficient to fund operations for at least the next twelve months" (10-Q lines 603-605), eliminating the going concern qualification. The restructuring in May 2025 — while correct in direction — was arguably 12-18 months late. The CGD program consumed significant capital before being abandoned despite having only ≈1,200 addressable US patients.

On the positive side: the BMS collaboration was well-structured ($55M upfront + $55M equity + $3.5B milestones for reagent work that leverages PRME's platform without consuming internal clinical development resources). CFF funding ($39M) is non-dilutive for CF development. The $300M ATM shelf is in place but has not been used, showing capital discipline.

Sources: PRME 8-K (May 19, 2025); DEF 14A (Jul 14, 2025); 8-K (Aug 5, 2025); yfinance insider transaction data.

Factor Profile

Regression Analysis (251 Trading Days)

Base Model (SPY + XBI):

Factor       β        Variance Contribution
SPY        +0.21        1.2%
XBI        +1.97       24.3%
Idio                   74.5%

α = +33.5% annualized | σ_idio = 98.5% | R² = 25.5%

Extended Model (+BEAM):

Factor       β        Variance Contribution
SPY        +0.24        1.3%
XBI        +0.68        8.5%
BEAM       +0.66       27.0%
Idio                   63.2%

α = +63.6% annualized | R² = 36.8%

Interpretation

This is a company bet. Market beta is effectively zero — SPY explains 1.2% of PRME's variance regardless of model specification. This stock does not move with the S&P 500.

The "biotech sector" exposure is really gene editing platform exposure. When BEAM is added as a factor, XBI's variance contribution drops from 24.3% to 8.5%. BEAM alone explains 27% of PRME's variance — more than the entire biotech sector ETF. The explanation: shared founder (David Liu), shared IP licensor (Broad Institute), overlapping disease targets (AATD), and shared technology narrative. When gene editing sentiment shifts, PRME and BEAM co-move.

Idiosyncratic variance: 74.5% (base) or 63.2% (with BEAM). The base model hits the 75% Paleologo threshold. Adding BEAM drops idio below target, but BEAM correlation is itself part of the thesis (arbitration outcome is an idiosyncratic catalyst that will either break or tighten the correlation).

The backward-looking alpha (33-64% annualized) is inflated by the +73% 1Y rally and recent +32% weekly move. Forward alpha is entirely pipeline-dependent and not extrapolable from historical returns.

Total volatility: 114%. Idiosyncratic volatility: 98%. Any position in PRME delivers outsized variance. A 2% allocation has the return impact of a 4-5% position in a normal-volatility stock.

Edge Audit

Edge-weighted variance: ≈70-80% (idio plus partial credit for BEAM arbitration insight).

Sources: iev regress PRME (multiple specifications); yfinance ticker data.

Forward Expectations Gap Analysis

What Current Price Requires

Market cap:              $800M
Estimated current cash:  ≈$150M (Sep 30 $213M less ≈$63M operating cash burn for ≈1.5 quarters)
Implied pipeline value:  ≈$650M

Note: Operating cash burn was $125.3M for 9M 2025 ($41.8M/quarter), materially below net loss of $155M ($51.7M/quarter) due to non-cash charges (SBC $24.8M, depreciation $5.4M, non-cash lease $7.1M). Cash estimates use operating cash flow, not net loss.

For a pre-revenue biotech, every dollar above cash is a probability-weighted bet on pipeline success.

Program-by-program decomposition of ≈$650M implied pipeline value:

The critical implied assumption: The market prices AATD at $200-250M, implying approximately 50% probability that PRME retains the program through arbitration AND 10-15% probability of clinical success. If PRME definitively loses the AATD arbitration, pipeline value drops to ≈$375-425M, implying fair value of approximately $2.90/share (-34%).

Street Estimates vs. Filing Reality

FY2026 EPS disconnect. Street models -$0.96 EPS, implying ≈$180M total opex — a 20% reduction from Q3 2025's annualized $221M. But: facility costs are rising (new Cambridge HQ lease, +47% YoY), personnel cuts are already in-run-rate, and IND-enabling work for two programs requires increased R&D spending. Getting from $221M to $180M requires additional cuts not yet disclosed. Q4 2025 earnings (Feb 27, 2026) will clarify whether this reduction has materialized.

Options-Implied Probabilities

Expiration     ATM IV    Key Strike/Delta           Implied Probability
Mar 2026 (21d)  77%      —                          Earnings catalyst
Apr 2026 (49d)  99%      —                          Post-earnings vol
Jul 2026 (140d) 100%     —                          IND filing window
Jan 2027 (322d) 115%     $5C: δ=0.67               67% prob > $5
Jan 2028 (693d) 120%     $5C: δ=0.82, $12C: δ=0.64 82% prob > $5, 64% prob > $12

Methodology caveat: Option delta approximates risk-neutral probability, not real-world probability. For a stock with 115-120% IV, the risk-neutral measure materially overstates real-world probability of finishing in-the-money because it embeds the volatility premium. The Jan 2028 $12 call delta of 0.64 does NOT mean "64% chance of reaching $12." A rough real-world adjustment for 120% IV over 2 years might put the actual probability at 35-45%. That said, even 35-45% probability of reaching $2.2B market cap requires positive clinical data from both Wilson Disease and AATD, favorable arbitration resolution, and no material dilution — a combination of outcomes whose joint probability is likely 20-30%.

The P/C ratio is 0.04 on near-term options (calls 23x puts). Even in Jan 2028 LEAPS, puts remain a small fraction (P/C 0.46). There is minimal downside hedging activity for a stock with 24.5% short interest and an active arbitration threatening its second-largest pipeline program.

Sources: yfinance options chain data; PRME 10-Q (Nov 7, 2025); stockanalysis.com analyst consensus.

Key Risks

1. BEAM Arbitration Over AATD — Existential for the Thesis

On April 16, 2025, Beam Therapeutics filed arbitration with the American Arbitration Association alleging PRME breached their September 2019 Collaboration and License Agreement by developing PM647 for AATD. PRME counter-filed on April 18, 2025.

The contractual issue. The 2019 agreement grants BEAM exclusive rights to prime editing for "qualifying Prime Editing agents" that make transition mutations (C→T, T→C, A→G, G→A). The AATD PiZ mutation (E342K) is a G→A transition — squarely within the literal scope of BEAM's exclusive field.

PRME's likely defense: PM647 uses a prime editing approach that does not qualify as a "qualifying Prime Editing agent" under the contract definition — meaning it either makes non-transition edits or uses a broader editing mechanism that falls within PRME's retained field. The contract carves PRME's field as "a Prime Editing agent that is not a qualifying Prime Editing agent."

What BEAM seeks: Declaratory, injunctive, and monetary relief. The maximum adverse outcome: PRME is ordered to cease AATD work and transfer the program to BEAM. BEAM also alleges trade secret misappropriation and failure to comply with technology transfer obligations.

Asymmetry. BEAM's 10-Q (Nov 4, 2025) states: "We are not currently subject to any material legal proceedings." The arbitration is immaterial to a $3.8B company with $1.08B in cash. For PRME at $800M, the AATD program is worth an estimated $200-250M of market cap. The proceedings are in "early stages" as of the last filing. No timeline for resolution has been disclosed.

Source: PRME 10-Q (Nov 7, 2025) lines 1392-1413; BEAM 10-Q (Nov 4, 2025) line 2743; PRME 10-K (Feb 28, 2025) lines 1545-1614.

2. Cash Runway — Tighter Than Guided

Management guided cash sufficient "into 2027." At Q3 2025's burn rate ($50-55M/quarter), $213M funds through Q3 2026 — not "into 2027." The guidance implicitly assumes FY2026 opex reduction that has not yet appeared in reported numbers. If Q4 2025 opex remains above $50M, the company will need additional capital before Wilson Disease data in 2027.

The $300M ATM shelf with Jefferies is available but unused. Any ATM sales at current prices (≈$4.42) would be highly dilutive to a $800M market cap.

3. Facility Cost Overhang

The new Cambridge HQ lease contributed to a 47% YoY increase in facility-related R&D expenses ($11.4M vs $7.8M in Q3 2024). Operating lease liabilities total ≈$118M long-term. This is a fixed commitment that does not flex with headcount reductions, partially negating the restructuring savings.

4. Clinical Execution Risk

Both liver programs are in IND-enabling stage. PRME has never filed an IND for an in vivo program. The PM359 (CGD) IND was ex vivo and used a different delivery modality. LNP delivery to liver is less novel (NTLA has demonstrated it with NTLA-2001 for ATTR), but PRME's specific formulation has not been tested in humans. Any delay in IND filing (H1 2026 for Wilson, mid-2026 for AATD) would pressure the cash runway timeline.

5. Broad Institute License Termination

Broad can terminate the license if PRME fails to use commercially reasonable efforts to develop licensed products or misses milestones. The September 2025 amendments adjusted milestones post-restructuring, but Broad retains this right going forward. Loss of the Broad license would be catastrophic — it is the foundation of PRME's entire technology platform.

6. Short Interest and Volatility

24.5% short interest with 8.2 days to cover creates asymmetric price dynamics. Positive catalysts (IND acceptance, arbitration win) could trigger forced covering. Negative catalysts (arbitration loss, IND delay, capital raise) could accelerate downward moves. With 114% total volatility, position sizing must account for potential 30-50% drawdowns on adverse news.

7. Regulatory Environment

The 10-Q added new risk factors regarding FDA disruption from government cost-cutting, personnel losses, and potential shutdowns. With two IND filings planned in H1-mid 2026, any delay in FDA review capacity directly impacts PRME's timeline and, by extension, its cash runway.

8. David Liu Conflict

David Liu is a founder of both PRME and BEAM. He sits on PRME's scientific advisory capacity and is a Broad Institute faculty member (the licensor). He has been buying PRME stock with personal cash. The BEAM-PRME arbitration creates a conflict of interest — Liu has financial interests on both sides of the dispute, though his recent purchasing pattern suggests alignment with PRME.

The Short Thesis (24.5% SI, 8.2 Days to Cover)

Nearly a quarter of the float is short. The bear case is coherent and not stupid:

1. Cash runway math doesn't work. $150M cash, $42M/quarter burn, two IND-enabling programs plus Cambridge HQ lease. Management says "into 2027" but the math says Q3 2026 without additional financing. A capital raise at $4.42 is ≈4% dilution per $30M raised. To fund through Wilson Disease data (2027), they need 4-5 quarters of runway = ≈$170M in additional capital. That's 20%+ dilution.

2. The pipeline is a science project. Zero human dosing for any liver program. The CGD data (ex vivo, blood cells) tells you nothing about LNP delivery to hepatocytes in humans. The mouse and NHP data is necessary but not sufficient. NTLA has already shown LNP-liver editing works in humans with NTLA-2001 — PRME's specific formulation is unproven.

3. AATD is legally encumbered. The BEAM arbitration could remove $200-250M of implied market cap overnight. And even if PRME wins the arbitration, they're 6th to the AATD party behind BEAM-302 (25+ patients, RMAT, accelerated approval path).

4. The +73% 1Y rally priced in the restructuring recovery. Insiders bought at $1-3. Stock is now $4.42. The easy money is made. From here, you need actual clinical catalysts to justify holding.

5. Broad license is a ticking clock. If PRME can't hit development milestones (adjusted or not), Broad can terminate. The entire technology platform evaporates.

Assessment: The short thesis is strongest on cash runway and AATD legal risk. It's weakest on timing — with 8.2 days to cover and multiple potential positive catalysts (IND filings, arbitration ruling, earnings beat), the squeeze risk is real. The shorts need the stock to die slowly, but the catalyst calendar is dense.

LR Signal: 1.0

Translation: This memo doesn't find a clear mispricing. The market is roughly right at $800M.

Bull case for higher LR: $15.4M insider buying cluster (ARCH $10M, GV $5M, David Liu, CEO — all open market) is one of the strongest insider signals possible for a sub-$1B biotech. The breadth matters: founder, board investor, AND new CEO all buying at the trough suggests private information or at minimum strong conviction. Wilson Disease competitive position is genuinely defensible. The Broad license is a real moat.

Bear case for lower LR: The insiders bought at $1-3, not at $4.42. The stock has already repriced +73% to reflect the restructuring. FY2026 street estimates assume opex cuts not yet visible in filings. AATD arbitration risk is underappreciated — the PiZ mutation IS a G→A transition, squarely within BEAM's exclusive field. Cash runway requires a raise that dilutes 20%+.

Why 1.0: The bull and bear cases roughly cancel at current price. The insider buying signal was powerful at $1-3 but has been consumed by the rally. The risks (arbitration, cash, clinical) are real but known. The market is pricing PRME as a speculative platform bet with two shots on goal (Wilson + AATD), minus litigation risk — which is approximately correct. There's no clear divergence between our analysis and market pricing.

Where edge could emerge: An analyst with primary insight into (a) the arbitration legal merits, (b) the LNP in vivo translational gap, or (c) BMS's internal view of the CAR-T collaboration could develop a view that diverges from market. This coverage initiation identifies the questions — it doesn't answer them.

What to Watch

Near-term (Q1 2026):

• Q4 2025 earnings (Feb 27, 2026): The single most important near-term data point. Q4 opex below $45M validates the restructuring and street's FY2026 models. Above $50M means the "almost halved cash needs" narrative is not yet reality. Cash balance update will recalibrate runway estimates.
• Wilson Disease IND filing (H1 2026): On-track signals from the Q4 call. Any language suggesting delay or additional preclinical work needed is a red flag for both timeline and cash.
• BEAM arbitration updates: Any disclosure of timeline, preliminary rulings, or settlement discussions. BEAM's next 10-K (late Feb/early Mar) may provide their first substantive disclosure.

Mid-term (Q2-Q3 2026):

• PM577 IND acceptance: FDA response to Wilson Disease IND is the first true clinical de-risking event.
• PM647 AATD IND filing (mid-2026): Contingent on arbitration resolution or PRME's willingness to file while litigation is pending.
• CF proof-of-concept data: Expected 2026. Lung delivery of gene editing has not been demonstrated by any company — positive data would be transformative for platform value.
• Capital raise: If burn rate remains $50M+/quarter, additional financing will be needed before year-end 2026. Watch the ATM facility for any share sales.

Long-term (2027):

• Wilson Disease Phase 1 clinical data: The event that determines whether prime editing works in vivo in humans for a liver indication. All other pipeline programs depend on this platform validation.
• AATD clinical data (if program retained): Comparison vs. BEAM-302's existing dataset will determine competitive viability.
• Arbitration resolution: The outcome will either validate PRME's $200-250M of AATD market cap or remove it.

Appendix: Related Counterparty Positions

BEAM Therapeutics (BEAM)

BEAM holds 1,608,337 shares of PRME common stock (from the 2019 collaboration), valued at ≈$7.1M at current prices. BEAM recorded $7.3M of income from PRME stock appreciation in the first nine months of 2025. BEAM is simultaneously litigating against PRME in the AATD arbitration while benefiting financially from PRME's stock appreciation — an unusual dynamic.

BEAM's AATD program (BEAM-302) is in Phase 1/2 with 25+ patients dosed, has RMAT designation, and is pursuing accelerated approval. BEAM raised $470.5M in a March 2025 offering at $28.48/share and has $1.08B in cash and marketable securities. BEAM describes the PRME arbitration as not constituting a "material legal proceeding" in its 10-Q.

Bristol-Myers Squibb (BMS)

BMS invested $55M in PRME equity as part of the September 2024 collaboration (11,006,163 shares). BMS is the counterparty on the CAR-T collaboration ($55M upfront + up to $3.5B in milestones). PRME carries $66.7M of deferred revenue related to this agreement. Separately, BMS acquired Orbital Therapeutics (in which BEAM held a 17% stake) for $1.5B in October 2025, creating an indirect BMS-BEAM financial linkage.

Broad Institute

PRME's exclusive licensor. Broad received 623,529 shares at inception plus nominal amendment fees. Broad is entitled to: annual maintenance fees (low six figures), up to $20M clinical/regulatory milestones per product, up to $54M sales milestones per product, mid-single-digit royalties on licensed products. Change-of-control triggers milestone payment increases. Broad amended the license twice in September 2025 to adjust development milestones post-restructuring. PRME's $5M pledge to fund David Liu's lab at Broad creates additional financial interconnection.

Cystic Fibrosis Foundation (CFF)

CFF has committed $39M ($15M in Jan 2024 + $24M in Jul 2025) for CF development. The $24M second tranche includes $6M cash (recorded as liability) + $6M equity investment + $12M milestone-contingent. CFF's royalty funding is repayable at up to 2.5x on change of control. Total potential CFF repayment obligation in an acquisition scenario: ≈$45M.